Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Infliximab

Infliximab: An Overview of Its Uses, Mechanism, and Benefits in Autoimmune Disorders

Introduction

Infliximab is a biologic drug that plays a pivotal role in the treatment of several autoimmune disorders. As a monoclonal antibody, it targets tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine that is central to the inflammatory processes in many chronic diseases. The development and use of infliximab have revolutionized the management of conditions like rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis.

Infliximab

Infliximab (brand name Remicade) is a chimeric monoclonal antibody, meaning it is composed of both human and mouse protein sequences. It is designed to bind specifically to TNF-α, a cytokine that plays a crucial role in the inflammatory response. By inhibiting TNF-α, infliximab effectively reduces inflammation and prevents the damage caused by autoimmune diseases. The drug is primarily administered via intravenous infusion, making it a treatment option for patients who require constant monitoring and cannot take oral medications.

Mechanism of Action

TNF-α is a pro-inflammatory molecule that is implicated in the pathogenesis of many chronic inflammatory diseases. It promotes the release of other inflammatory cytokines, chemokines, and enzymes, and plays a role in the recruitment of immune cells to sites of inflammation.

Infliximab binds to soluble and transmembrane forms of TNF-α, inhibiting its interaction with TNF receptors on cell surfaces. This action results in:

  • Reduction in pro-inflammatory cytokine production

  • Decreased immune cell activation

  • Inhibition of inflammatory processes

By neutralizing TNF-α, infliximab reduces inflammation and suppresses the immune system’s attack on the body’s own tissues.

Clinical Uses of Infliximab

Infliximab is used to treat several autoimmune and inflammatory conditions. The following are the most common indications for infliximab therapy:

1. Rheumatoid Arthritis (RA)

Rheumatoid arthritis is a chronic inflammatory disorder characterized by the progressive destruction of joints and tissues. Infliximab is used as part of combination therapy with methotrexate to control symptoms and prevent joint damage. By targeting TNF-α, infliximab reduces the inflammatory response that leads to cartilage and bone destruction.

Efficacy: Studies have shown that infliximab significantly improves functional status, reduces joint damage, and relieves symptoms in RA patients.

2. Crohn's Disease

Crohn’s disease is a chronic inflammatory bowel disease that causes inflammation of the gastrointestinal tract. Infliximab is used to treat moderate to severe Crohn's disease, particularly in patients who have not responded to other treatments like corticosteroids or immunosuppressive drugs.

Efficacy: Infliximab helps achieve clinical remission, reduces inflammation, and improves the quality of life for individuals with Crohn’s disease. It is also effective in healing fistulas, which are common complications of the disease.

3. Ulcerative Colitis

Ulcerative colitis is another form of inflammatory bowel disease that affects the colon. Infliximab is approved for use in patients with moderate to severe ulcerative colitis who have not responded to conventional therapy. 

Efficacy: Similar to its effects in Crohn’s disease, infliximab reduces inflammation, helps induce and maintain remission, and is useful in preventing flare-ups in ulcerative colitis patients.

4. Psoriasis

Psoriasis is a chronic autoimmune skin disorder characterized by the rapid growth of skin cells that leads to thick, scaly patches. Infliximab is used for moderate to severe plaque psoriasis, particularly when other treatments like topical therapies and phototherapy have failed.

Efficacy: Infliximab has shown significant improvement in skin lesions, reducing the severity of psoriasis and improving overall skin health.

5. Ankylosing Spondylitis

Ankylosing spondylitis is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints. Infliximab helps control inflammation, reduce pain, and improve mobility in patients with ankylosing spondylitis.

Efficacy: Infliximab has been proven to significantly reduce the disease’s symptoms and slow down the progression of spinal fusion.

6. Other Indications

Infliximab has been used off-label for a variety of other autoimmune conditions, including:

  • Psoriatic arthritis

  • Juvenile idiopathic arthritis

  • Giant cell arteritis

  • Systemic lupus erythematosus (SLE)

Administration and Dosing

Infliximab is administered through intravenous infusion in a healthcare setting. The typical dosing schedule is:

  • Initial dose: A dose of 5 mg/kg is given at 0, 2, and 6 weeks.

  • Maintenance doses: Following the initial course, the medication is typically administered every 8 weeks.

For patients with certain conditions, the dosing schedule may be adjusted. Infliximab infusion typically lasts 2–3 hours, and patients are monitored for any adverse reactions during the infusion.

Side Effects and Adverse Reactions

As with any biologic therapy, infliximab carries the risk of side effects. Some patients may experience mild symptoms, while others may encounter more serious reactions. Common side effects include:

Common Side Effects:

  • Infusion-related reactions (fever, chills, headache, nausea, dizziness)

  • Upper respiratory tract infections (e.g., sinusitis, nasopharyngitis)

  • Headache

  • Nausea and vomiting

Serious Side Effects:

  • Infections: Infliximab suppresses the immune system, making patients more susceptible to infections such as tuberculosis, fungal infections, and viral infections.

  • Cancer: Long-term use of TNF inhibitors like infliximab has been associated with an increased risk of certain cancers, including lymphoma and skin cancers.

  • Heart failure: Infliximab can exacerbate pre-existing heart failure, and it should be used with caution in patients with a history of heart failure.

  • Hepatotoxicity: There have been reports of liver damage, including hepatitis and liver failure, in patients using infliximab.

  • Autoimmune reactions: In rare cases, patients may develop autoantibodies and symptoms of lupus-like syndrome, including joint pain, skin rashes, and fatigue.

Delayed Hypersensitivity Reactions:

  • Patients may experience delayed reactions, including fever, chills, or rashes, 3–12 days after receiving an infusion. These reactions may require further treatment or discontinuation of infliximab therapy.

Monitoring During Treatment

Patients on infliximab therapy require regular monitoring to ensure efficacy and detect potential adverse effects. Recommended monitoring includes:

  • Tuberculosis screening: Prior to starting therapy, all patients should be tested for tuberculosis (TB), as infliximab can increase the risk of reactivation.

  • Liver function tests: Periodic checks of liver enzymes are necessary, especially for those with a history of liver issues.

  • Complete blood count (CBC): To monitor for blood dyscrasias or infections.

  • Signs of infection: Vigilant monitoring for signs of infection during treatment is crucial, as infliximab increases susceptibility.

Contraindications

Infliximab is contraindicated in patients with:

  • Active infections (especially tuberculosis, fungal infections, or viral hepatitis)

  • Severe heart failure (NYHA class III/IV)

  • Hypersensitivity to infliximab or any of its components

  • Pregnancy: Infliximab is classified as pregnancy category B, which means it should only be used when necessary and prescribed by a healthcare provider.

Patient Considerations and Education

Patients should be educated on the following aspects of infliximab therapy:

  1. Infusion Reactions: Patients should be informed about the possibility of infusion reactions and be advised to notify their healthcare provider if they experience symptoms such as fever, chills, or trouble breathing during or after the infusion.

  2. Infection Risks: Patients must be educated about the increased risk of infections and the importance of seeking medical attention if symptoms of infection (e.g., fever, persistent cough) arise.

  3. Adherence: Given the need for regular intravenous infusions, adherence to the treatment schedule is critical to achieve and maintain optimal results.

  4. Vaccinations: Patients should be up-to-date with their vaccinations before starting infliximab therapy, particularly for hepatitis B, influenza, and pneumococcal vaccines.

Conclusion

Infliximab is a powerful biologic therapy that has transformed the management of several autoimmune diseases. By targeting TNF-α, it effectively reduces inflammation, alleviates symptoms, and improves the quality of life for patients with conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis. Although it is associated with certain risks, including infections and potential cancer risks, its benefits in controlling chronic inflammation and preventing disease progression are well-established. With appropriate patient selection, monitoring, and education, infliximab offers significant therapeutic benefits, making it a key treatment option for many individuals with autoimmune conditions. As research continues to evolve, it is likely that infliximab will remain an important tool in the management of inflammatory diseases for years to come.